| Outcome Measures: |
Primary: Urinary proximal tubule cells changes in protein expression of inflammatory genes such as p16ink4a, TLR-4, phospho-p65, DKK3, Myostatin, TGFβ, SMAD 2,3 and MAPK pathways., baseline and every 3 months up to 18 month|Urinary proximal tubule cells changes in genes such as type IV collagen fibronectin, TGF-β, TNF receptor 1, EMF cadherin production, NF-kB, MCP-1 , DKK3, myostatin and Activin A, baseline and every 3 months up to 18 month|Biopsy changes in the expression and location of senescence markers by immunohistochemistry, In the first six patients with T2DM, proteinuria \> 1 g/day and biopsy proven diabetic kidney disese allocated to the treatment with dapagliflozin, we will investigate the following changes in expression and location of p16inkA, SA-beta-galactosidase, TNF receptor 1, EMF cadherin NF-kB., Baseline and after 6 month | Secondary: Changes in BOLD MRI, Changes in global and segmental renal oxygenation estimated by BOLD MRI (changes in R2\* value defined as 1/T2\*) at 12 and 24 weeks, Baseline and after 3 month|Urinary markers of interstitial fibrosis, Changes in urinary markers of a proxy of interstitial fibrosis in patients with CKD (Mir 20), Baseline and every 3 months up to 18 month|Changes in urinary albumin excretion, Changes in urinary albumin excretion, Baseline and every 3 months up to 18 month|Changes in eGFR, decrease of eGFR ml/min \> 30%, Baseline and every 3 months up to 18 month|Outcomes of blood presssure control, changes in blood pressure values and in the need of antihypertensive drugs, Baseline and every 6 months up to 18 month
|
